Clearing Zombie Cells
Senolytic therapy targets senescent cells—often called 'zombie cells'—that stop dividing but remain in the body, causing chronic inflammation and aging.
2026 Clinical Success
New localized senolytic delivery systems are showing promise in treating osteoarthritis and age-related vision loss.
Official Insight
The NIH Geroscience interest group is currently overseeing Phase III trials for senolytic compounds.
Strategic Data Expansion 2026.4
A major 2026 breakthrough involved the use of 'targeted' senolytics that only activate in the presence of specific inflammatory markers. This reduces the risk of side effects while maximizing the clearance of dysfunctional cells.
[Diagram showing a senolytic molecule attaching to a senescent cell]
Researchers at the Mayo Clinic reported in March 2026 that clearing these cells in the musculoskeletal system resulted in a 20% increase in mobility for elderly participants.